Neurology

The codirector of the MDA Clinic and professor of neurology at Johns Hopkins discussed updated data from the NURTURE study.

The chief scientific officer of LocanaBio discussed preclinical research presented at ASGCT 2023.

The chief medical officer of Forge Biologics discussed updated data from the phase 1/2 RESKUE clinical trial that she presented at ASGCT’s 2023 conference.

Review top news and interview highlights from the week ending July 21, 2023.

Gary Owens, MS, the associate director for gene therapy discovery at Precision Biosciences, discussed data he presented at ASGCT’s 2023 conference.

The chief scientific officer at REGENXBIO discussed RGX-202 and the ongoing clinical trial.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The professor of neurosurgery at Rush University Medical School discussed challenges with trials for SCI and the 1st Annual SCIIS.

The pediatric gastroenterologist and professor in residence at University of California at San Francisco discussed biomarker findings from the phase 1/2 CAMPSIITE trial.

The associate director for gene therapy discovery at Precision Biosciences discussed preclinical research he presented at ASGCT’s 2023 conference.

Review top news and interview highlights from the week ending July 14, 2023.

The guidance outlines recommendations for managing and reporting CGT manufacturing changes and PMR noncompliance.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The senior investigator at the National Cancer Institute Center for Cancer Research discussed unmet needs that remain and further research to be done.

Wave Life Sciences is discontinuing WVE-004.

Reductions in NfL were also associated with changes on ALSFRS-R scores.

Review top news and interview highlights from the week ending July 7, 2023.

Among 29 patients who were treated with nusinersen in the RESPOND trial and evaluable for efficacy, most demonstrated an increase in mean total HINE-2 score from baseline.

In terms of safety, Capricor Therapeutics’ CAP-1002 was reported to be well-tolerated.

The professor at Ohio State University and University of California – San Francisco discussed investigations with different delivery methods of GDNF gene therapy.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Review top news and interview highlights from the week ending June 30, 2023.

Taysha also provided updates on its gene therapy program for Rett syndrome.

Benitec Biopharma is planning to initiate a phase 1b/2a clinical trial to evaluate BB-301.

Detailed topline data will be presented at the 2023 International Congress on Parkinson’s Disease and Movement Disorders in August.